CSSV yields 500000.00% · ABBV yields 3.12%● Live data
📍 CSSV pulled ahead of the other in Year 1
Combined, CSSV + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CSSV + ABBV for your $10,000?
Caspian Services, Inc. provides various oilfield services for the oil and gas industry in the Republic of Kazakhstan and the Caspian Sea region. The company operates in three segments: Vessel Operations, Geophysical Services, and Marine Base Services. The Vessel Operations segment charters a fleet of shallow draft offshore support vessels to oil and natural gas exploration companies. This segment's vessel fleet includes supply vessels, survey/utility vessels, anchor handling multicats and support vessel tugs, cable laying barges, accommodation vessels, and crewboats. The Geophysical Services segment offers onshore geophysical services to independent oil and gas exploration and development companies operating in Kazakhstan. This segment provides geophysical seismic surveys, such as 2D and 3D seismic surveys. The Marine Base Services segment operates a marine base located at the Port of Bautino on the North Caspian Sea. This segment offers various facilities and services comprising long and short terms vessel moorings, wharf front crane pad for vessel loading/offloading, boat yard with vessel lifting facilities, long-term berths, water storage facilities and vessel bunkering, oily and waste water collection and removing facilities, weighbridge facilities, electrical power supply and distribution systems, and open lay-down storage area. The company was formerly known as EMPS Corporation and changed its name to Caspian Services, Inc. in July 2005. Caspian Services, Inc. was founded in 1998 and is based in Almaty, Kazakhstan.
Full CSSV Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.